Johns Hopkins Hospital

Milestone Scientific Commences Sales of CompuFlo® Epidural Disposables within PRC Alliance Pain Relief Center in Ormond Beach, Florida

Retrieved on: 
Wednesday, April 3, 2024
Johns Hopkins Hospital, MLSS, Anesthesia, Risk, Trauma, MD, ESI, CPT, ASC, Injection, Safety, Spine, Pain management, Pain, Physician, Epidural steroid injection, Nursing

ROSELAND, N.J., April 03, 2024 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced that it has commenced sales of CompuFlo® Epidural disposables into PRC Alliance Pain Relief Center at Ormond Beach, Florida. PRC Alliance Pain Relief Centers operates 7offices and an ambulatory surgical center (ASC) located across Central Florida, with 15 providers. PRC Alliance Pain Relief Centers is a family of pain management specialists who are dedicated to relieving pain through exceptional and compassionate care.

Key Points: 
  • ROSELAND, N.J., April 03, 2024 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced that it has commenced sales of CompuFlo ® Epidural disposables into PRC Alliance Pain Relief Center at Ormond Beach, Florida.
  • PRC Alliance Pain Relief Centers operates 7offices and an ambulatory surgical center (ASC) located across Central Florida, with 15 providers.
  • PRC Alliance Pain Relief Centers is a family of pain management specialists who are dedicated to relieving pain through exceptional and compassionate care.
  • Adoption of the technology follows a successful evaluation by Dr. Sanjay Bakshi, MD, a pain management physician and CEO of PRC Alliance Pain Relief Centers in Ormond Beach, Florida.

NAHQ Announces 2024 Board Members

Retrieved on: 
Monday, April 8, 2024
Hospital, RN, Health, ChristianaCare, Health care, CHC, CAE, Patient safety, RNC-NIC, RRT, Lifespan, Safety, Workforce, National Association, MHA, Organization, Trinity Health, University, MJ, Senior, Nursing, Trinity, Einstein Medical Center Philadelphia, Trinity Health (Livonia, Michigan), Johns Hopkins Hospital, CPPS, Texas Children's Hospital, Doctor of Philosophy, MBA, Quality, Fesler

CHICAGO, April 8, 2024 /PRNewswire/ -- The National Association for Healthcare Quality® (NAHQ) has announced its new board members and leadership positions: Patricia Resnik, MJ, MBA, RRT, FACHE, CPHQ, CHC, CHPC, as its 2024 president; April M. Taylor, MS, MHA, FACHE, CMQ/OE, CLSSBB, CPHQ, CPPS, as president-elect; Cathy Duquette, PhD, MBA, RN, NEA-BC, CPHQ, FNAHQ, as secretary/treasurer; and Sheranda Fesler, PhD, RN, RNC-NIC, NE-BC, CPHQ, CPPS, FNAHQ, as chair of the individual strategic advisory council.

Key Points: 
  • "It is an honor to welcome these industry leaders as they step into their new roles on the board.
  • "It is my privilege to serve as the NAHQ president this year with such a distinguished group of quality colleagues," Resnik stated.
  • "As my work with NAHQ deepens each year, so does my affinity for and dedication to its purpose and vision.
  • "I am deeply honored to bring my experience, passion and commitment to healthcare quality and safety to my role on the NAHQ board," said Fesler.

OKYO Pharma to Host Key Opinion Leader Event to Discuss New and Comprehensive Data from Phase 2 Dry Eye Disease Trial

Retrieved on: 
Thursday, March 21, 2024
Visual Science, Uveitis, Wilmer Ophthalmological Institute, Brandeis University, Neurophysiology, NCP, BID, Telecanthus, Research, KOL, University, Patient, Doctor of Philosophy, Bascom Palmer Eye Institute, DED, Georgetown University Medical Center, Pain, Therapy, Johns Hopkins Hospital, Medical director, FDA, Pharmaceutical industry

LONDON and NEW YORK, March 21, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of inflammatory dry eye disease (DED), a multi-billion-dollar market, and anterior ocular segment diseases including neuropathic corneal pain (NCP), an ocular condition associated with pain but without an FDA approved therapy, announces that it will be hosting a Key Opinion Leader (KOL) event on April 9th, 2024 at 12:00 PM ET to discuss in depth the findings of the new and comprehensive efficacy data readout from the Phase 2 trial of OK-101 in dry eye disease, which will be announced on March 22nd, 2024.

Key Points: 
  • OKYO Pharma’s management team will also be in attendance to present an overview of OK-101’s mechanism of action.
  • He has published over 200 peer-reviewed articles and has served on the editorial boards of several prestigious ophthalmology journals.
  • Additionally, statistically significant improvements were observed in both a “sign” (total conjunctival staining) and two “symptoms” (burning/stinging and blurred vision), which are FDA-recognized endpoints of dry eye disease.
  • The double-masked, randomized, placebo-controlled Phase 2 trial was conducted at six sites in the U.S. and enrolled 240 subjects with DED dosed twice-daily (BID).

Healthy.io and Johns Hopkins Collaborate to Utilize New Patient-Facing Technology to Improve Wound Care Management

Retrieved on: 
Thursday, March 7, 2024
Diabetes, Caregiver, Telehealth, Vascular surgery, Manuscript, Communication, Risk, Amputation, Frontiers, Johns Hopkins, COVID-19, Prediabetes, Patient, Privacy, DFU, CDC, Research, Johns Hopkins Hospital, Wound healing, Nursing

BOSTON, March 7, 2024 /PRNewswire/ -- Healthy.io, the global leader in transforming the smartphone camera into a medical device, is launching a groundbreaking program utilizing smartphone-based technology to improve wound care management for patients suffering from chronic diabetic wounds. This pilot program expands access to Healthy.io's Minuteful for Wound solution to patients in the division of Vascular Surgery and Endovascular Therapy department at the Johns Hopkins Hospital.

Key Points: 
  • This pilot program expands access to Healthy.io's Minuteful for Wound solution to patients in the division of Vascular Surgery and Endovascular Therapy department at the Johns Hopkins Hospital.
  • Diabetes and chronic wounds are often connected, with 19-33% of patients with diabetes developing diabetic foot ulcers (DFU) or other chronic wound conditions in their lifetime.
  • Despite health systems' enthusiasm for telemedicine after the COVID-19 pandemic, research documenting the impact of patient-centered technologies on wound care is scarce.
  • "We are thrilled to be collaborating with Johns Hopkins to utilize this innovative technology, which empowers patients and their caregivers to take an active role in their wound care management," said Geoff Martin, CEO of Healthy.io.

Dr. Ben Carson & Dr. Michael Beckwith Pray for the Nation on Super Tuesday, Hosted by Soaak Technologies

Retrieved on: 
Wednesday, March 6, 2024
Theta, Nation, Love, Freedom, EMDR, Housing, Hope, Death, Super, Health, Safety, Thermography, Brain mapping, Pediatric neurosurgery, God the Father, Agape International Spiritual Center, Metabolic typing, Pan American Health Organization, Patient, Neurosurgery, Low-level laser therapy, Former, Consciousness, Johns Hopkins Hospital, Beauty, Medical device

TULSA, Okla., March 6, 2024 /PRNewswire/ -- Soaak Technologies, Inc. (https://www.soaak.com/), a health-tech company known for their clinically proven sound frequency composition therapies, welcomed Dr. Ben Carson and Dr. Michael Beckwith for Super Tuesday 2024 to visit the new state of the art Soaak Clinic located in Tulsa Oklahoma, noting the importance of advancements in technology in health and wellness being a matter that should have extreme attention on both sides of the political aisle heading into the 2024 elections. Dr. Ben Carson being the Chief of Pediatric Neurosurgery at Johns Hopkins Hospital, Former United States Secretary of Housing and Urban Development, and Former Presidential Candidate (2016), and Dr. Michael Beckwith, author, and founder and spiritual director of the Agape International Spiritual Center, along with Soaak Executives, led a prayer focused on healing and uniting the nation. The visit comes on the heels of the U.S. Air Force Awarding Soaak Technologies a second contract to Enhance Airmen's Performance, using their proprietary Sound Frequency Compositions.

Key Points: 
  • "We are honored that Dr. Ben Carson and Dr. Michael Beckwith joined us at our Soaak Clinic to bear witness to how we are affecting change on such a notable day for America.
  • To kickstart the Super Tuesday event, Soaak Executive Chairman Henry Penix, alongside Dr. Ben Carson and Dr. Michael Beckwith, led a prayer for the Nation.
  • Dr. Ben Carson began the prayer by saying, "Heavenly Father, we gather here in gratitude for the peace, safety, and freedom we enjoy.
  • "I was honored to meet Dr. Carson for the first time and join him in prayer for our Nation on this Super Tuesday," stated Dr. Michael Beckwith.

SCHOCHOR, STATON, GOLDBERG AND CARDEA, P.A. AND JANET, JANET & SUGGS, LLC TO OPPOSE THE ARCHDIOCESE OF WASHINGTON'S MOTION TO DISMISS ITS CLASS ACTION LAWSUIT IN UPCOMING HEARING

Retrieved on: 
Monday, February 12, 2024
Chairperson, General assembly, Child, Survivor, Hearing, Minor, Assembly, Goldberg, Language, Clergy, Conference, History, Personal injury, Immunity, Circuit court, Johns Hopkins Hospital

BALTIMORE, Feb. 12, 2024 /PRNewswire/ -- Schochor, Staton, Goldberg and Cardea, P.A. and Janet, Janet & Suggs, LLC, two leading Maryland-based medical malpractice, personal injury, and civil litigation law firms, are partnering to oppose a motion to dismiss a class action lawsuit against the Archdiocese of Washington in an upcoming March hearing on behalf of sex abuse victims who have come forward seeking justice. 

Key Points: 
  • The class action against the Archdiocese of Washington was filed the same day.
  • The Archdiocese of Washington has requested that the lawsuit be dismissed, arguing that the Child Victims Act is unconstitutional.
  • and Janet, Janet & Suggs, LLC, on behalf of the plaintiffs, argue that the 2017 law was not a "statute of repose."
  • and Janet, Janet & Suggs, LLC, have previously partnered in a class action against Johns Hopkins Hospital arising from sexual abuse committed by one of its doctors.

Face Expert Dr. Georges J. Samaha Joins Exclusive Haute Beauty Network

Retrieved on: 
Wednesday, January 31, 2024
Augmented fifth, Surgeon, Breast augmentation, Mount Sinai Hospital, Alpha Omega Alpha, Family, Breast, Travel, Plastic surgery, AOA, Rhinoplasty, Patient, Philosophy, Plastic, FDA, Johns Hopkins Hospital, Nobel Prize, Journal, BBL, University, Beauty, Medicine, Textbook, Craniofacial, Mastopexy, Hospital, Dentistry

NEW YORK, Jan. 31, 2024 /PRNewswire-PRWeb/ -- Dr. Georges Samaha is double-board certified by the American Board of Plastic Surgery. He is a diplomate of the American Board of Plastic Surgery as well as a diplomate of the American Board of Surgery. Dr. Samaha has specific interests in various aspects of facial plastic surgery — including deep plane facelift, neck lift, rhinoplasty, and eyelid rejuvenation — as well as breast and body contouring procedures. Patients travel from around the world for the above procedures including breast augmentation, breast lifts, high-definition tummy tucks, natural buttock augmentation using fat transfer known as the Brazilian Butt Lift ("BBL"), and his special natural high-definition liposuction with abdominal etching technique. Dr. Samaha's array of popular procedures can provide patients with beautiful, natural curves and are truly life-changing.

Key Points: 
  • Dr. Georges J. Samaha joins Haute Beauty Network as a face expert representing the Miami, FL market.
  • NEW YORK, Jan. 31, 2024 /PRNewswire-PRWeb/ -- Dr. Georges Samaha is double-board certified by the American Board of Plastic Surgery.
  • He is a diplomate of the American Board of Plastic Surgery as well as a diplomate of the American Board of Surgery.
  • Dr. Samaha has specific interests in various aspects of facial plastic surgery — including deep plane facelift, neck lift, rhinoplasty, and eyelid rejuvenation — as well as breast and body contouring procedures.

The Inner Circle Acknowledges, Aaron T. Scott, DHA(c), CNMT, NMAA, FSNMMI-TS as a Distinguished Professional for his work in healthcare

Retrieved on: 
Monday, January 22, 2024
Nuclear medicine, Capella University, Master, BLS, Medical college, NMAA, Professional, Health care, Molecular biophysics, Health, Inner circle, Clark Atlanta University, Johns Hopkins Hospital, Mediocre, DHA, ACLS, IRB, Spectrum, GLEN, Teaching, Publication, Health administration, Nursing

GLEN BURNIE, Md., Jan. 22, 2024 /PRNewswire/ -- Aaron T. Scott, DHA(c), CNMT, NMAA, FSNMMI-TS is being recognized by The Inner Circle as a Distinguished Professional for his work in healthcare.

Key Points: 
  • GLEN BURNIE, Md., Jan. 22, 2024 /PRNewswire/ -- Aaron T. Scott, DHA(c), CNMT, NMAA, FSNMMI-TS is being recognized by The Inner Circle as a Distinguished Professional for his work in healthcare.
  • A dedicated healthcare professional with a wealth of experience and expertise.
  • As Vice President of Clinical Operations, Aaron holds a pivotal role at the Advanced Molecular Imaging & Therapy in Glen Burnie, MD.
  • He has held leadership positions in professional organizations, received awards, and made significant contributions to the field through publications and educational speaking engagements.

INOVIO to Participate in Virtual Fireside Chat on the Potential Treatment of Recurrent Respiratory Papillomatosis with Key Opinion Leader

Retrieved on: 
Monday, January 22, 2024
Patient, University, Biology, RRP, CSL Behring, Polyp, Principal, MD, Associate, Therapy, DNA, Fireside chats, TB, Stenosis, Tuberculosis, Novo Nordisk, Business administration, Johns Hopkins Hospital, Novartis, Cancer, Disease, Spasmodic dysphonia, Cyst, Johns Hopkins, Bachelor, Infection, Recurrence, MBA, Royal college, CMO, NIH, Shire (pharmaceutical company), Otorhinolaryngology, Human, Medical research, Emergent, Research, Vaccine, Oppenheimer Holdings, Laryngeal cancer, Pharmaceutical industry

PLYMOUTH MEETING, Pa., Jan. 22, 2024 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer and infectious diseases, today announced that it will participate in a virtual fireside chat on the potential treatment of Recurrent Respiratory Papillomatosis (RRP). INOVIO's President and CEO, Dr. Jacqueline Shea, and Chief Medical Officer, Dr. Michael Sumner, will be joined by Dr. Simon Best, Otolaryngologist at Johns Hopkins University and a Principal Investigator in INOVIO's Phase 1/2 trial with INO-3107.

Key Points: 
  • The fireside chat, titled "RRP - Disease Treatment Dynamics & Urgent Need for Therapeutic Modalities," will take place on Wednesday, January 24, 2024, at 12:00pm ET.
  • Hartaj Singh, MBA, Managing Director of Biotechnology Equity Research at Oppenheimer & Co. Inc., will moderate the discussion.
  • He is a fellowship-trained laryngeal surgeon whose clinical interests are focused on voice and airway disorders, with a particular interest in RRP.
  • Prior to joining INOVIO, she was the CEO at Aeras, a not-for-profit organization dedicated to developing new vaccines against tuberculosis (TB).

ImmunoBrain Checkpoint Appoints Dr. Sanjay Keswani as Chief Executive Officer

Retrieved on: 
Monday, January 22, 2024
Bristol Myers Squibb, Neurophysiology, Patient, MD, Sanjay, Medicine, St Bartholomew's Hospital, Johns Hopkins Hospital, Johns Hopkins, Royal College of Physicians, Immunology, Saint Mary's Hospital, Acquisition, Royal college, Bachelor of Science, CMO, IPO, Bartholomew the Apostle, Fibrosis, Hospital, Series A round, FRCP, Roche, Faricimab, Growth, Pharmaceutical industry

NEW YORK, Jan. 22, 2024 /PRNewswire/ -- ImmunoBrain Checkpoint Inc. (ImmunoBrain), a clinical stage biopharmaceutical company developing innovative disease-modifying immune therapies to combat neurodegenerative diseases, today announced the appointment of Dr. Sanjay Keswani, MD, BSc, FRCP, as its President and Chief Executive Officer.

Key Points: 
  • NEW YORK, Jan. 22, 2024 /PRNewswire/ -- ImmunoBrain Checkpoint Inc. (ImmunoBrain), a clinical stage biopharmaceutical company developing innovative disease-modifying immune therapies to combat neurodegenerative diseases, today announced the appointment of Dr. Sanjay Keswani, MD, BSc, FRCP, as its President and Chief Executive Officer.
  • Dr. Keswani is an accomplished physician-scientist with executive leadership experience in both large pharma and small biotech companies.
  • "As a physician-scientist and seasoned biotech executive, Dr. Keswani possesses both the business acumen and the R&D expertise required to serve as Chief Executive Officer of ImmunoBrain," stated Nathan Hevrony, Co-founder and Executive Chairman of ImmunoBrain.
  • I am privileged to work with the ImmunoBrain team and Professor Michal Schwartz whose groundbreaking seminal research has formed the foundation of ImmunoBrain," stated Dr. Sanjay Keswani.